The Food and Drug Administration advised Chiasma Inc. (Nasdaq: CHMA) that its New Drug Application for the acromegaly treatment Mycapssa did not provide substantial evidence of efficacy to warrant approval and recommended and additional clinical trial. Shares of the biopharmaceutical plummeted $6.24 to $3.93.
FDA advises Chiasma to conduct additional trial
April 18, 2016 at 13:54 PM EDT
